Subscribe to this collection to receive daily e-mail notification of new additions

	Title	Author(s)	Issue Date
	Increased colonization of lactococcus lactis could prevent development of non-alcoholic fatty liver disease: evidence from a human microbiota-associated rodent model Proceeding/Conference:Hepatology	Tun, HMZhang, SLee, CHPChau, HTZhang, DLiang, SHuang, FYWong, DKHLam, KSLYuen, RMFSeto, WKW	2020
	A prospective study of the impact of glycaemic status on clinical outcomes and anti-SARS-CoV-2 antibody responses patients with predominantly non-severe COVID-19 Proceeding/Conference:Journal of Diabetes Investigation	Lui, TWDLi, YKLee, CHPChow, WSLee, CHATam, ARPang, KPPHo, TYCheung, YYFong, HYTo, KKWTan, KCBWoo, YCHung, FNILam, KSL	2021
	The impact of post-operative hypoparathyroidism on fractures in a territory-wide cohort of elective total thyroidectomy for benign diseases: a 10-year follow-up Proceeding/Conference:World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO), 2021	Lui, TWDFung, MHMLee, CHPFong, HYWoo, YCLang, HHB	2021
	Cost-effectiveness of poly ADP-ribose polymerase inhibitors in ovarian cancer treatment: a systematic review Proceeding/Conference:The Health Technology Assessment International (HTAi) Annual Meeting	Chan, KYVChan, YLALau, KWWong, ICKLi, X	2021
	Consumption and expenditure on monoclonal antibodies and Fc-fusion protein biologic medicines in Asia-Pacific regions. Proceeding/Conference:ISPE's 13th Asian Conference on Pharmacoepidemiology (ACPE) and the 28th Conference of Korean Society for Pharmacoepidemiology and RiskManagement (KoPERM)	Tong, XLi, XHillen, JPratt, NWong, ICK	2021
	Circulating tenascin-C levels predict renal progression in type 2 diabetes Proceeding/Conference:57th Annual Meeting of the European Association for the Study of Diabetes	Lui, TWDLee, CHPCheung, YYFong, HYChow, WSWoo, YCLam, KSL	2021
	AB-729, a GalNAc-siRNA, results in robust reductions of HBV DNA and HBsAg in subjects with chronic hepatitis B infection Proceeding/Conference:Hepatology International	Sevinsky, HGane, EDGane, EBerliba, EKim, YJHolmes, JLim, Y-SStrasser, SSukeepaisarnjaroen, WSchwabe, CJucov, ALee, ACHThi, EPHarasym, TPamulapati, GRWattamwar, PKunta, JSofia, MSevinsky, HGray, KEley, TPicchio, GSims, KDYuen, RMF	2021
	Preliminary results of a Phase 2 study of VIR-2218, an X-targeting RNAi therapeutic, in patients with chronic hepatitis B: sub-analyses of HBeAg-negative and HBeAg-positive patients Proceeding/Conference:Hepatology International	Yuen, RMFLim, YSCloutier, DShen, LCathcart, ADing, XArizpe, APang, PHuang, SGane, E	2021
	Regression of liver fibrosis after HBsAg loss: a prospective matched case-control evaluation using transient elastography and serum Enhanced Liver Fibrosis (ELF) test Proceeding/Conference:Hepatology International	Mak, LYWong, DKHHui, WHRCheung, KSMLiu, FFung, JYYSeto, WKWYuen, RMF	2021
	Analysis of longer-term safety profile of the hepatitis B virus core inhibitor ABI-H0731 in an open label extension study Proceeding/Conference:Hepatology	Jacobson, IMMa, XNguyen, TSchiff, ERYuen, RMFHann, HWLSulkowski, MSNahass, RGRamji, AAgarwal, KPark, JSAyoub, WSGane, EJKnox, SAlves, KLi, YFStamm, LMWeilert, FBennett, MHan, SHBRavendhran, NChan, SKwo, PYElkhashab, MHassanein, TFung, SKBae, HLalezari, JPDieterick, DT	2020
	Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels – a multicenter study (CREATE) Proceeding/Conference:Hepatology	Sonneveld, MJPark, JYKaewdech, ASeto, WKWTanaka, YCarey, IPapatheodoridi, MVan Bömmel, FBerg, TZoulim, FAhn, SHDalekos, GNErier, NSHöner zu SiederdissenC, CWedemeyer, HComberg, MYuen, RMFAgarwal, KBoonstra, AFerret, MABPiratvisuth, TPapatheodoridis, GMaasoumy, BCREATE study group,	2020
	Safety and pharmacodynamics of the GALNAC-siRNA AB-729 in subjects with chronic hepatitis B infection Proceeding/Conference:Hepatology	Yuen, RMFBerliba, EKim, YJHolmes, JALim, YSStrasser, SISchwabe, CJucov, ALee, ACHThi, EPHarasym, TPamulapati, GRWattamwar, PKunta, JSofia, MJSevinsky, HGray, KEley, TPicchio, GRSims, KGane, EJ	2020
	Nicotinic acetylcholine receptor subunit alpha 7 mediates cigarettes smoke-induced PD-L1 expression in human bronchial epithelial cells Proceeding/Conference:Hong Kong Medical Journal	Kwok, HHGao, BLee, CMNDeng, JMIp, MSMMinna, JDLam, CLD	2021
	Association of aspirin with lung carcinoma in patients with chronic obstructive pulmonary Proceeding/Conference:Hong Kong Medical Journal	Yu, SYIp, MSMLi, XCheung, KSMRen, QLi, HKWong, PFTse, HFYiu, KY	2021
	Factors associated with sleep apnoea prevalence in patients with stroke: a systemic review and meta-analysis Proceeding/Conference:Hong Kong Medical Journal	Liu, XDLam, CLDChan, HYAIp, MSMLau, GKK	2021
	HBsAg loss is higher among caucasians compared to Asians after stopping nucleos(t)ide analogue therapy: results from a large, global, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study) Proceeding/Conference:Hepatology	Hirode, GChoi, HSJSu, THWong, GLHSeto, WKWHees, SVPapatheodoridi, MBrakenhoff, SLens, SSarowar, AChien, RNForns, XSonneveld, MJPapatheodoridis, GVanwolleghem, TYuen, RMFChan, HLYKao, JHHsu, YCChen, CHHansen, BECornberg, MJeng, WJJanssen, HLARETRACT-B Study Group,	2020
	Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors Proceeding/Conference:Journal of Hepatology	Gane, ELocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, ODe Ridder, FCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF	2021
	A phase 1 study evaluating the neutralizing, vaccinal monoclonal antibody VIR-3434 in participants with chronic hepatitis B virus infection Proceeding/Conference:Journal of Hepatology	Agarwal, KYuen, RMFWedemeyer, HCloutier, DShen, LArizpe, APang, PTay, CGupta, SVCathcart, AGane, E	2021
	Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results Proceeding/Conference:Journal of Hepatology	Gane, ELim, YSCloutier, DShen, LCathcart, ADing, XPang, PHuang, SYuen, RMF	2021
	A single dose of the GalNAc-siRNA, AB-729, results in prolonged reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA in the absence of nucleos (t)ide analogue therapy in HBeAg negative subjects with chronic hepatitis B infection Proceeding/Conference:Journal of Hepatology	Gane, ESevinsky, HYuen, RMFAnderson, MCloherty, GThi, EPWattamwar, TSofia, MJGray, KAntoniello, DEley, TPicchio, GSims, K	2021